Report: GSK Mulls Deal for India Vaccines Unit

GlaxoSmithKline is reportedly eyeing the vaccines division of India's Biological E for greater manufacturing capacity in India. The BE vaccines buyout may allow GSK to boost share on the subcontinent and export greater quantities to international markets, the Economic Times reports.

Officials from GSK's Belgium-based biologicals business recently visited Biological E's manufacturing facility in Shameerpet, India, near Hyderabad, sources told the newspaper. GSK's current plant in Nashik, India, has recently faced difficulties supplying enough vaccines for export, a pharma analyst told the